17 May 2012, BioSpectrum Bureau , BioSpectrum
Bangalore: Pharma majors Lupin and Aurobindo have announced that they have received approvals for their respective generic versions of Combivir tablets used in the treatment of HIV. Aurobindo Pharma received the tentative US FDA approval to manufacture and market fixed dosed combination Abacavir Sulfate / Lamivudine Tablets 60/30mg.
The company had earlier received tentative approvals to co-packaged Lamivudine / Zidovudine Tablets + Abacavir Sulfate Tablets 150/300mg + 300mg and Abacavir Sulfate / Lamivudine Tablets 600/300 mg, used in combination therapy. This is Aurobindo's 87th ANDA approval from US FDA (61 Final approvals, 26 Tentative approvals).
Moreover, Lupin also announced that its subsidiary Lupin Pharmaceuticals received the final approval for its Lamivudine and Zidovudine tablets 150/200mg tablets. The press release added that Lupin has already commenced the shipping of the product.